ストックスクリーナーアプリを入手
4.216
0.86%
0.036
アフターアワーズ：
4.12
-0.096
-2.28%
前日終値:
$4.18
開ける：
$4.16
24時間の取引高:
19,556
Relative Volume:
0.07
時価総額：
$12.98M
収益：
-
当期純損益:
$-29.77M
株価収益率:
-0.2756
EPS:
-15.2954
ネットキャッシュフロー:
$-24.23M
1週間 パフォーマンス:
+7.83%
1か月 パフォーマンス:
+4.10%
6か月 パフォーマンス:
-74.53%
1年 パフォーマンス:
-59.85%
1日の値動き範囲:
$4.07
$4.2601
1週間の範囲:
$3.85
$4.3884
52週間の値動き範囲:
$3.13
$91.25
Moleculin Biotech Inc Stock (MBRX) Company Profile
Compare MBRX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
4.216 | 12.87M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-09 | 再開されました | H.C. Wainwright | Buy |
| 2025-02-12 | ダウングレード | Maxim Group | Buy → Hold |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
Moleculin Biotech Inc (MBRX) 最新ニュース
Moleculin at Corporate Connect: Annamycin’s Promising Future By Investing.com - Investing.com Canada
Moleculin Biotech: Annamycin's Phase 3 trial nears key data, with strong efficacy and major market potential - TradingView
Moleculin Biotech: Annamycin's phase 3 trial in AML offers near-term data and major market potential - TradingView
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moleculin Biotech stockholders approve warrant issuance, reject name change By Investing.com - Investing.com South Africa
Moleculin Biotech stockholders approve warrant issuance, reject name change - Investing.com
Moleculin Biotech Shareholders Approve Warrant Share Issuance - TipRanks
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - marketscreener.com
Aug Final Week: Is MNDO a play on infrastructure spending2025 Technical Patterns & Real-Time Market Sentiment Reports - baoquankhu1.vn
AI Stocks: Can Moleculin Biotech Inc maintain sales growth2025 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
What are Home Bancshares Inc. (Conway AR)’s growth leversMarket Risk Analysis & Fast Moving Stock Trade Plans - baoquankhu1.vn
Aug Intraday: Can Moleculin Biotech Inc maintain sales growthTrade Ideas & High Accuracy Swing Trade Signals - baoquankhu1.vn
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference - intellectia.ai
Will Moleculin Biotech Inc. benefit from geopolitical trendsRate Hike & Smart Investment Allocation Insights - mfd.ru
Moleculin Biotech Updates Investors with New Corporate Presentation - TipRanks
Aug Spikes: What are Moleculin Biotech Incs earnings expectations2025 Geopolitical Influence & Safe Entry Zone Identification - baoquankhu1.vn
New brain cancer trial tests WP1066 plus radiation in glioblastoma - Stock Titan
MBRXMoleculin Biotec Latest Stock News & Market Updates - Stock Titan
Moleculin’s Annamycin shows no cardiotoxicity in cancer trials By Investing.com - Investing.com Nigeria
Moleculin’s Annamycin shows no cardiotoxicity in cancer trials - Investing.com
Moleculin Highlights Non-Cardiotoxic Profile of Lead Annamycin Drug - TipRanks
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects - The Manila Times
Moleculin Biotech, Inc. Reports No Cardiotoxicity in Annamycin Trials - TradingView — Track All Markets
Moleculin Biotech, Inc. Reports No Evidence of Cardiotoxicity for Annamycin Across Five Clinical Trials - Quiver Quantitative
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - MSN
Moleculin expects first MIRACLE trial data readout in Q1 2026 By Investing.com - Investing.com Nigeria
Moleculin Biotech (MBRX) Readies Annamycin for Major Milestones in 2026 - GuruFocus
Moleculin expects first MIRACLE trial data readout in Q1 2026 - Investing.com
Moleculin Biotech advances Annamycin AML Phase 3 program - TipRanks
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs - The Manila Times
Moleculin Biotech, Inc. Announces Milestones and Upcoming Unblinding for MIRACLE Trial in Acute Myeloid Leukemia and New Pancreatic Cancer Initiatives - Quiver Quantitative
Moleculin accelerates outlook into 2026 with first pivotal trial unblinding on track, global trial expansion, and multiple externally/IIT funded clinical programs - marketscreener.com
Moleculin Biotech, Inc. Accelerates 2026 Outlook with Key Clinical Trials - TradingView
Experimental chemo aiming to spare the heart nears key 2026 trial test - Stock Titan
Moleculin Biotech prices $5.9M public offering; shares down about 47% - MSN
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
Buy Signal: Why Moleculin Biotech Inc. stock could rally in 20252025 Stock Rankings & Weekly Chart Analysis and Trade Guides - Улправда
What technical charts say about Moleculin Biotech Inc. stockGap Up & Reliable Breakout Stock Forecasts - Улправда
Why retail investors favor Moleculin Biotech Inc. stockEarnings Miss Alerts & Free Fast Track Wealth Growth - ulpravda.ru
Moleculin Biotech, Inc.Common Stock (Nasdaq:MBRX) Stock Quote - FinancialContent
Why Moleculin Biotech Inc. stock is considered a top pickMarket Insider Reports & Budget Friendly Trading Strategies - Улправда
Moleculin Biotech regains Nasdaq listing compliance - marketscreener.com
Moleculin Biotech Regains Compliance With Nasdaq Listing Requirements - TipRanks
Moleculin Biotech Regains Nasdaq Compliance - TradingView
Why Moleculin Biotech Inc. stock remains a top recommendation2026 world cup usa national team round of 32 midfield engines counter attacking tactical prediction breakdown - Улправда
Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN
Moleculin Biotech’s Wild Ride: Is Tiny-Cap MBRX the Next Viral Moonshot or Total Trap? - AD HOC NEWS
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Moleculin Biotech enters inducement offer agreements - MSN
Moleculin Biotech begins dosing subjects in combination therapy trial for AML - MSN
Moleculin Biotech Inc (MBRX) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):